Skip to main content

David J. Dykeman to Speak at ACI’s Summit on Life Sciences IP Due Diligence

BOSTON – Nov. 4, 2020 – David J. Dykeman, co-managing shareholder of global law firm Greenberg Traurig, LLP’s Boston office and co-chair of the firm's global Life Sciences & Medical Technology Group, will be a speaker during American Conference Institute’s (ACI) 4th Annual Summit on Life Sciences IP Due Diligence, taking place virtually Nov. 9-10, 2020.

On Monday, Nov. 9, Dykeman will moderate the session, "Unique IP Due Diligence Considerations for Medical Devices, MedTech, and Artificial Intelligence." The panel session will address the unique considerations that companies face when approaching IP due diligence projects involving medical devices and inventions based on AI.

The session’s panelists include:

Jeremy Bond, Senior Counsel, Device Patents in U.S. Global Intellectual Property Dept. at Sanofi (Cambridge, MA)
Mark D. Kafka, Associate Director, Assistant General Counsel at Genentech, Inc. (South San Francisco, CA)
Jeff Mann, Senior Vice President, General Counsel and Secretary at Cantel Medical (Little Falls, NJ)

The Annual Summit on Life Sciences IP Due Diligence is devoted to providing life sciences and legal professionals with expert strategies for assessing, valuing, and commercializing IP assets when conducting strategic IP due diligence. This year’s virtual format will provide an interactive forum for discussing best practices and developing strategies for preparing for, conducting, and applying the results of the IP due diligence process.

Dykeman is a registered patent attorney with more than 23 years of experience in patent and intellectual property law. His practice focuses on securing worldwide intellectual property protection and related business strategies for high tech clients, with particular experience in life sciences, medical devices, robotics, materials, and information technology. An author of over 50 articles and a speaker at over 45 conferences on intellectual property law, he is the founding co-chair of the ABA’s Medical Devices Committee. David has also been named one of the top 250 Patent and Technology Licensing Practitioners in the world by Intellectual Asset Management (IAM) Magazine, an "IP Star" by Managing IP magazine, a "Life Science Star" by LMG Life Sciences, one of the World's Leading IP Strategists in the IAM 300, and is listed in Chambers.

About Greenberg Traurig’s Life Sciences & Medical Technology Group: Greenberg Traurig’s Life Sciences & Medical Technology Group advises clients ranging from start-ups to large multinational public companies to leading research institutions. The group’s attorneys work closely with clients, providing innovative legal counsel to help them achieve their objectives – from discovery through commercialization and product marketing.

About Greenberg Traurig: Greenberg Traurig, LLP (GT), has approximately 2200 attorneys in 40 locations in the United States, Latin America, Europe, Asia, and the Middle East. GT has been recognized for its philanthropic giving, diversity, and innovation, and is consistently among the largest firms in the U.S. on the Law360 400 and among the Top 20 on the Am Law Global 100. The firm is net carbon neutral with respect to its office energy usage and Mansfield Rule 3.0 Certified. Web: